This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in JAMA  Social Bookmarking   What's this?

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

To the Editor: Dr Schrag and colleagues¹ provided information that is critical for making the difficult decision of prophylactic mastectomy in women with breast cancer and BRCA1 or BRCA2 mutations.

However, several issues would further enhance the value of their work. First, the results are stated as the average life expectancy gain, which can be misleading. An increase of 1 year in average life expectancy does not imply that an individual woman can anticipate an extra year of life. Rather, this gain reflects the average benefit in a cohort of women at a defined age and level of risk. It is important to note that the benefit of surgery would be unevenly distributed. In the absence of prophylaxis, a higher percentage of women will experience a recurrence, from which a certain percentage will die. The benefit of prophylaxis is only in this group that would have died. For the majority, . . . [Full Text of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED ARTICLE

Life Expectancy Gains From Cancer Prevention Strategies for Women With Breast Cancer and BRCA1 or BRCA2 Mutations
Deborah Schrag, Karen M. Kuntz, Judy E. Garber, and Jane C. Weeks
JAMA. 2000;283(5):617-624.
ABSTRACT | FULL TEXT